Lexeo Therapeutics
LXEO
109 hedge funds and large institutions have $327M invested in Lexeo Therapeutics in 2025 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 50 increasing their positions, 15 reducing their positions, and 7 closing their positions.
271% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 7
233% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 15
93% more capital invested
Capital invested by funds: $170M → $327M (+$158M)
21% more funds holding
Funds holding: 90 → 109 (+19)
35.91% less ownership
Funds ownership: 127.25% → 91.34% (-36%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
76% less call options, than puts
Call options by funds: $27K | Put options by funds: $111K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$11.7M |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$6.71M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.26M |
| 4 |
6CM
683 Capital Management
New York
|
+$4.46M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$4.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$4.76M |
| 2 |
ABG
Ally Bridge Group
New York
|
-$3.49M |
| 3 |
Millennium Management
New York
|
-$2.53M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$461K |
| 5 |
QC
Quadrature Capital
London,
United Kingdom
|
-$120K |
LXEO Hedge Fund Activity: Q3 2025 in Review
109 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Lexeo Therapeutics (LXEO) for Q3 2025, worth a combined $327M — up 93% from $170M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new LXEO positions and 7 closed out — a net gain of 19 holders — while 50 added to existing stakes and 15 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $11.7M. The largest seller was Omega Fund Management, exiting entirely with an estimated $4.76M sold.
- 109 institutional investors held Lexeo Therapeutics (LXEO) as of Q3 2025, up from 90 in Q2 2025.
- Funds reported $327M of Lexeo Therapeutics stock for Q3 2025, up 93% quarter-over-quarter.
- 26 funds opened new Lexeo Therapeutics positions in Q3 2025 and 7 closed out, a net change of +19 holders.
- The largest Lexeo Therapeutics buyer in Q3 2025 was Janus Henderson Group, an estimated $11.7M added.
- The largest Lexeo Therapeutics seller in Q3 2025 was Omega Fund Management, an estimated $4.76M sold.
Based on aggregated 13F filings for Q3 2025.